- Solutions Overview
- Clinical Development
- Outsourcing Services
- Parexel® Biotech
- Medical Affairs
- Real-World Evidence and Late Phase
- Our Company
- Management Team
- Diversity, Equity and Inclusion
- Career Opportunities
- Trust & Privacy
July 2 - July 3, 2021
Predictive modelling to examine long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s disease.
Maciej Maruszczak,1 Ken Genenz,2 Erika Turkstra,1 Elisabetta Fenu,2 Gary Hantsbarger,3 Inmaculada Gilaberte,4 Chitra Karki3 and Julian Panes5
1Parexel International, Uxbridge, UK; 2Takeda Pharmaceuticals, Zurich, Switzerland; 3Takeda Pharmaceuticals, Cambridge, MA, USA; 4Takeda Pharmaceuticals, Madrid, Spain; 5Gastroenterology Department, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
We are always available for a conversation.